Our Goal
The goal of the High-Throughput Truthing (HTT) project is to produce a validation dataset established by pathologist annotations for artificial intelligence algorithms analyzing digital scans of pathology slides: data (images + annotations). We are pursuing the qualification of the final validation dataset as an FDA-qualified medical device development tool MDDT to become a high-value public resource that can be used in AI/ML algorithm submissions and guide others to develop quality validation datasets.
- Here is a project overview: Dudgeon2021_J-Pathol-Inform_v12p45.
- Other selected works from this project can be found on our Publications Page.
Why is the FDA Doing This?
Artificial intelligence (AI) promises to reduce pathologist burden searching and evaluating cells and features on the slides; let the computer do it. AI also promises to help the pathologists be more quantitative and less variable. The regulatory question is then, “How well can the computer algorithms do the tasks?” The most practical ground truth for evaluating algorithm performance is pathologist interpretations of the whole slide images. The problem is that pathologist interpretations can vary greatly between and within pathologists. Therefore, we need to acknowledge this variability, reduce this variability, and then account for this variability. Tools, methods, and research in this area are lacking, so we are doing it. In this work, we collect data that demonstrates pathologist variability, we create training materials to reduce pathologist variability, and we develop methods to investigate and account for pathologist variability.
Project Context
The HTT project is a collaborative project that crowdsources pathologist annotations. The annotations we are collecting are estimates of the density of stromal tumor-infiltrating lymphocytes (sTILs) in breast cancer. sTILs are a prognostic biomarker (Salgado2015_Ann-Oncol_v26p259, Loi2019_J-Clin-Oncol_v37p559). This project will additionally produce statistical analysis tools to evaluate algorithm performance given the variance in the ground truth.
Our Methods
For our pilot study, we digitized 64 glass slides of stained ductal carcinoma core biopsies prepared at a single clinical site. A collaborating pathologist selected 10 regions of interest (ROIs) per slide for evaluation. We created training materials and workflows to crowdsource pathologist image annotations with two modalities: an optical microscope, eeDAP, an Evaluation Environment for Digital and Analog Pathology, and two digital platforms, caMicroscope, and Path Presenter. (More information in the next section). The annotation workflow asks the pathologist to evaluate the ROI type, make a decision on whether the ROI is appropriate for estimating the density of sTILs, and if appropriate, estimate amount of tumor-associated stroma in the ROI and the density of sTILs in the stroma. The pilot study data are publicly available HERE.
Technologies Used in this Project
Digital Platforms
We have two digital platforms for viewing and annotating whole slide images: PathPresenter and caMicroscope. Pathologists can log in from anywhere in the world and annotate images using these web-based viewers.
Leadership from Path Presenter and caMicroscope are collaborators on this project and have supported the development of controlled and standardized workflows to select and evaluate ROIs.
Microscope Platform
The optical microscope platform uses a hardware and software system called eeDAP, an Evaluation Environment for Digital and Analog Pathology Gallas2014_J-Med-Img_v1p037501. The eeDAP system registers the live-camera view of the microscope slide with a digital scan of the slide taken with a whole slide imaging system. The eeDAP system is programed to automatically move the motorized stage to pre-specified regions of interest (ROIs) within a slide, so that we can collect data in microscope or digital mode. Annotations collected on the microscope (the reference standard device) are free of degredations from slide digitization.